254 related articles for article (PubMed ID: 29461979)
1. Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.
Wu X; Guo J; Niu M; An M; Liu L; Wang H; Jin X; Zhang Q; Lam KS; Wu T; Wang H; Wang Q; Du Y; Li J; Cheng L; Tang HY; Shang H; Zhang L; Zhou P; Chen Z
J Clin Invest; 2018 Jun; 128(6):2239-2251. PubMed ID: 29461979
[TBL] [Abstract][Full Text] [Related]
2. Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment.
Ferrari G
J Clin Invest; 2018 Jun; 128(6):2189-2191. PubMed ID: 29683434
[TBL] [Abstract][Full Text] [Related]
3. Tandem bispecific antibody prevents pathogenic SHIV
Niu M; Wong YC; Wang H; Li X; Chan CY; Zhang Q; Ling L; Cheng L; Wang R; Du Y; Yim LY; Jin X; Zhang H; Zhang L; Chen Z
Cell Rep; 2021 Aug; 36(8):109611. PubMed ID: 34433029
[TBL] [Abstract][Full Text] [Related]
4. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.
Khan SN; Sok D; Tran K; Movsesyan A; Dubrovskaya V; Burton DR; Wyatt RT
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976677
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
Lin A; Balazs AB
Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
[TBL] [Abstract][Full Text] [Related]
6. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
Moshoette T; Ali SA; Papathanasopoulos MA; Killick MA
Retrovirology; 2019 Nov; 16(1):31. PubMed ID: 31703699
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.
Asokan M; Rudicell RS; Louder M; McKee K; O'Dell S; Stewart-Jones G; Wang K; Xu L; Chen X; Choe M; Chuang G; Georgiev IS; Joyce MG; Kirys T; Ko S; Pegu A; Shi W; Todd JP; Yang Z; Bailer RT; Rao S; Kwong PD; Nabel GJ; Mascola JR
J Virol; 2015 Dec; 89(24):12501-12. PubMed ID: 26446600
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
9. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
[TBL] [Abstract][Full Text] [Related]
10. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.
Huang Y; Yu J; Lanzi A; Yao X; Andrews CD; Tsai L; Gajjar MR; Sun M; Seaman MS; Padte NN; Ho DD
Cell; 2016 Jun; 165(7):1621-1631. PubMed ID: 27315479
[TBL] [Abstract][Full Text] [Related]
11. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
Brady JM; Baltimore D; Balazs AB
Immunol Rev; 2017 Jan; 275(1):324-333. PubMed ID: 28133808
[TBL] [Abstract][Full Text] [Related]
12. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
14. Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.
Khan L; Kumar R; Thiruvengadam R; Parray HA; Makhdoomi MA; Kumar S; Aggarwal H; Mohata M; Hussain AW; Das R; Varadarajan R; Bhattacharya J; Vajpayee M; Murugavel KG; Solomon S; Sinha S; Luthra K
Sci Rep; 2017 Mar; 7():45163. PubMed ID: 28332627
[TBL] [Abstract][Full Text] [Related]
15. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
16. Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target.
Sherpa C; Le Grice SFJ
Curr HIV Res; 2020; 18(2):114-131. PubMed ID: 32039686
[TBL] [Abstract][Full Text] [Related]
17. Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.
Steinhardt JJ; Guenaga J; Turner HL; McKee K; Louder MK; O'Dell S; Chiang CI; Lei L; Galkin A; Andrianov AK; A Doria-Rose N; Bailer RT; Ward AB; Mascola JR; Li Y
Nat Commun; 2018 Feb; 9(1):877. PubMed ID: 29491415
[TBL] [Abstract][Full Text] [Related]
18. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC
Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831
[TBL] [Abstract][Full Text] [Related]
19. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
20. Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.
Hale M; Mesojednik T; Romano Ibarra GS; Sahni J; Bernard A; Sommer K; Scharenberg AM; Rawlings DJ; Wagner TA
Mol Ther; 2017 Mar; 25(3):570-579. PubMed ID: 28143740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
